These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 30287171)

  • 1. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
    Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
    Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Nishida N; Kudo M
    Dig Dis; 2017; 35(6):618-622. PubMed ID: 29040995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies.
    Marquardt JU; Saborowski A; Czauderna C; Vogel A
    Target Oncol; 2019 Apr; 14(2):115-123. PubMed ID: 30805831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.
    Uhlig J; Stein S; Kim HS
    Future Oncol; 2022 May; 18(14):1691-1703. PubMed ID: 35172633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
    El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
    Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy of liver cancer.
    Demir T; Lee SS; Kaseb AO
    Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
    Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
    Moriguchi M; Umemura A; Itoh Y
    Clin J Gastroenterol; 2016 Aug; 9(4):184-90. PubMed ID: 27401471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
    Noonan A; Pawlik TM
    Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 36.